437 related articles for article (PubMed ID: 37638058)
21. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
[TBL] [Abstract][Full Text] [Related]
22. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
[TBL] [Abstract][Full Text] [Related]
23. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
[TBL] [Abstract][Full Text] [Related]
24. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic approaches to enhance natural killer cell cytotoxicity.
Stenger TD; Miller JS
Front Immunol; 2024; 15():1356666. PubMed ID: 38545115
[TBL] [Abstract][Full Text] [Related]
26. Antibody variable region engineering for improving cancer immunotherapy.
Lou H; Cao X
Cancer Commun (Lond); 2022 Sep; 42(9):804-827. PubMed ID: 35822503
[TBL] [Abstract][Full Text] [Related]
27. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Demaria O; Gauthier L; Vetizou M; Blanchard Alvarez A; Vagne C; Habif G; Batista L; Baron W; Belaïd N; Girard-Madoux M; Cesari C; Caratini M; Bosco F; Benac O; Lopez J; Fenis A; Galluso J; Trichard S; Carrette B; Carrette F; Maguer A; Jaubert S; Sansaloni A; Letay-Drouet R; Kosthowa C; Lovera N; Dujardin A; Chanuc F; Le Van M; Bokobza S; Jarmuzynski N; Fos C; Gourdin N; Remark R; Lechevallier E; Fakhry N; Salas S; Deville JL; Le Grand R; Bonnafous C; Vollmy L; Represa A; Carpentier S; Rossi B; Morel A; Cornen S; Perrot I; Morel Y; Vivier E
Cell Rep Med; 2022 Oct; 3(10):100783. PubMed ID: 36260981
[TBL] [Abstract][Full Text] [Related]
28. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
29. Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy.
Phung SK; Miller JS; Felices M
Mol Diagn Ther; 2021 Sep; 25(5):577-592. PubMed ID: 34327614
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
32. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
33. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
34. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
[TBL] [Abstract][Full Text] [Related]
35. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
36. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko NA; Zhigarev D; Campbell KS
Nat Rev Drug Discov; 2022 Aug; 21(8):559-577. PubMed ID: 35314852
[TBL] [Abstract][Full Text] [Related]
37. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas.
Pawlowski KD; Duffy JT; Tiwari A; Zannikou M; Balyasnikova IV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443750
[TBL] [Abstract][Full Text] [Related]
38. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
39. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
40. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.
Chin DS; Lim CSY; Nordin F; Arifin N; Jun TG
Curr Pharm Biotechnol; 2022; 23(4):552-578. PubMed ID: 34414871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
